Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00088504 | Merimepodib (MMPD) in Triple Combination for the Treatment of Chronic Hepatitis C | PHASE2 | COMPLETED | 315 | — | — | Jul 1, 2004 | Oct 1, 2006 | Dec 21, 2007 | 67 | United States |
| Name | Type | Description |
|---|---|---|
| Merimepodib | DRUG | - |
| PEG-Interferon-alpha 2a (Pegasys®) | DRUG | - |
| Ribavirin (Copegus®) | DRUG | - |
Inclusion Criteria: The following is a summary of the inclusion and exclusion criteria for the Merimepodib Triple Combination (METRO) trial. There are also additional criteria, which will be reviewed with you by the staff at the clinical study site, to make sure you are eligible for the study. Some...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Atea Pharmaceuticals, Inc. | AVIR | 2 | PHASE3 | Bemnifosbuvir-Ruzasvir, Sofosbuvir-Velpatasvir |
| Abbott Laboratories | ABT | 2 | — | Undisclosed |
| AbbVie, Inc. | ABBV | 1 | — | Undisclosed |